A shift toward making multiple medications under one roof is sparking concern about what happens when a facility suddenly shuts down because of a manufacturing or safety issue: Closing a single factory could lead to shortages of hundreds of drugs, say regulators and industry analysts

Quick Read

The latest flashpoint in the ongoing debate over high drug prices is Emflaza, an $89,000-a-year drug that treats Duchenne muscular dystrophy

Quick Read

A group of academic researchers has demanded an end to cancer medicines costing more than $100,000 a year and proposed a new model of low-cost drug development that would capitalize on recent advances in science

Quick Read

As we know by now, history often repeats itself. History, that is, which involves outlandish price hikes by pharmaceutical companies

Quick Read

In this town, carved into the Appalachian mountains, in a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach. Over the past year, only 3 percent of the state’s Medicaid beneficiaries with the disease received treatment

Quick Read

The Justice Department is investigating the pricing practices of several generic drug manufacturers because the list prices of many older medications have risen in lockstep in recent years

Quick Read

Dealmakers have always flipped companies. Lately, they’ve been flipping something else: aging pharmaceuticals

Quick Read

Martin Shkreli. Valeant Pharmaceuticals. Mylan. These names have become big news, but just a year ago, most Americans devoted little time and attention to the question of pharmaceutical pricing. Now, a Kaiser Health Tracking Poll released Oct. 27 suggests many people care more about the increasing prices of drugs than they do about any other aspect of health care reform

Quick Read